SCHEMBL3763939

SCHEMBL3763939

Fc1ccccc1-n1nnc(-c2nc(-c3ccccn3)no2)c1-c1ccncc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 11/20 0.55
PKM P14618 9/20 0.55
RAB9A P51151 9/20 0.55
SMN1; SMN2 Q16637 8/20 0.55
NPC1 O15118 8/20 0.55
ALDH1A1 P00352 3/20 0.55
GRM5 P41594 5/20 0.46
TSHR P16473 4/20 0.44
HSD17B10 Q99714 5/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
KLF5 Q13887 2/20 0.44
HPGD P15428 1/20 0.44
S1PR1 P21453 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3764576 0.92 RAB9A (0.49) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3764705 0.90 S1PR1 (0.44) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3761084 0.89 NPC1 (0.54) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3760855 0.87 NPC1 (0.52) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3757412 0.87 NPC1 (0.54) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3751170 0.86 TP53 (0.56) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3755430 0.85 NPC1 (0.50) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL10181574 0.85 TP53 (0.47) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3756773 0.84 S1PR1 (0.48) TP53PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3760882 0.84 NPC1 (0.51) TP53PKMRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
CN-101918395-B Triazole oxadiazole derivatives MERCK SERONO SA 2014-04-16 CN disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
WO-2009080663-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO S.A. (CH) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES OXA1L, RO60, PDCD11 TP53 2220/4885PKM 4116/4885RAB9A 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.